N
NeuralStem
Biotech & Life Sciences · Rockville, United States · Founded 1996 · IPO 2006
Neuralstem, a biotherapeutics company, aims to apply stem cell research and technology to treat diseases of the central nervous system MoreLess
Seneca Biopharma, Inc. (NASDAQ: SNCA) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases that currently lack effective medical solutions. Operating in the biopharmaceutical sector, Seneca focuses on identifying and acquiring promising new scientific assets and technologies. The company aims to build a robust pipeline of biopharmaceuticals, advancing these products through clinical development and ultimately commercializing them to create value for stakeholders.
Seneca Biopharma serves a diverse range of clients, including patients with unmet medical needs, healthcare providers, and research institutions. The company operates primarily in the healthcare and biotechnology markets, targeting diseases where current treatment options are inadequate or non-existent.
Seneca's business model revolves around the acquisition and development of novel biopharmaceutical assets. By leveraging a network of trusted experts and advisors, the company evaluates new technologies and integrates them into its development pipeline. Revenue generation is anticipated through the successful commercialization of these biopharmaceutical products, either independently or through strategic partnerships.
Keywords: biopharmaceutical, clinical-stage, novel treatments, unmet medical need, asset acquisition, pipeline development, biotechnology, healthcare, commercialization, NASDAQ SNCA.
Company overview
NeuralStem company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 1996
- Headquarters
- Rockville, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 56.5
Valuation & funding
NeuralStem funding history
Company financing events and reported valuations.
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $260K | 0% | −$15M | -5769.2% |
| 2025 | $260K | 0% | −$15M | -5769.2% |
| 2024 | $260K | 0% | −$15M | -5769.2% |
| 2023 | $260K | 0% | ||
| 2022 | $260K | 0% | ||
| 2021 | $260K | 0% | ||
| 2020 | $260K | — |
Growth signals
NeuralStem website traffic
Latest recorded traffic for NeuralStem is 220 monthly website visits, up 4.8% over the last three months. NeuralStem's team grew 0% over the past year.
Comparisons
NeuralStem compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
NeuralStem's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where NeuralStem has talent and traffic
In the news
Latest news about NeuralStem
Recent press, funding announcements, and product moves mentioning NeuralStem — open to read from the original sources.
Market sentiment
What the market is saying about NeuralStem
An AI-synthesized read of the highest-engagement posts about NeuralStem on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuralStem’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.